Načítá se...
Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
PURPOSE: PF-05280014 is a biosimilar to trastuzumab (Herceptin(®)). Following demonstration of pharmacokinetic (PK) similarity in healthy volunteers, a comparative clinical study in patients with HER2-positive metastatic breast cancer (mBC) compared the efficacy, safety and immunogenicity of PF-0528...
Uloženo v:
| Vydáno v: | Cancer Chemother Pharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Berlin Heidelberg
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6586910/ https://ncbi.nlm.nih.gov/pubmed/31053945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03850-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|